for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

SEIKAGAKU CORPORATION

4548.T

Latest Trade

1,164.00JPY

Change

-2.00(-0.17%)

Volume

28,400

Today's Range

1,162.00

 - 

1,171.00

52 Week Range

1,073.00

 - 

1,698.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Seikagaku says clinical trial for SI-449

May 21 (Reuters) - Seikagaku Corp <4548.T>:Says it will initiate a clinical trial (pilot study) in Japan for SI-449, an adhesion barrier for use in surgery .

Seikagaku announces new drug application approval of hernicore® 1.25 units for intradiscal injection in Japan

March 23(Reuters) - Seikagaku Corp <4548.T>:Says it announced that the Japanese Ministry of Health, Labour and Welfare has approved the new drug application of HERNICORE® 1.25 units for intradiscal injection in Japan, indicated for the treatment of lumbar disc herniation.

Seikagaku initiates a phase III clinical trial (additional study) in the U.S. for SI-6603

Feb 19 (Reuters) - Seikagaku Corp <4548.T>:Says it will initiate a Phase III clinical trial (additional study) in the U.S. for SI-6603, indicated for the treatment of radicular leg pain (i.e. sciatica) due to a lumbar disc herniation. .

Ribomic signs collaborative research contract with SEIKAGAKU

Nov 8 (Reuters) - Ribomic Inc <4591.T>:Says it signed collaborative research contract with SEIKAGAKU CORPORATION <<<4548.T>>>.Says two entities mainly cooperate on new technologies development of drug discovery related to Aptamers.

Seikagaku initiates phase II study of SI-613 for treatment of knee osteoarthritis in U.S.

June 16(Reuters) - Seikagaku Corp <4548.T>:Says it announces the start of phase II study of SI-613 in patients with osteoarthritis of the knee, in the U.S. .

Ono Pharmaceutical signs co-development and marketing collaboration agreement with Seikagaku

May 12(Reuters) - Ono Pharmaceutical Co Ltd <4528.T>:Says Seikagaku Corp <<<4548.T>>> and Ono Pharmaceutical Co., Ltd. have reached a basic agreement related to.co-development and marketing collaboration on SI-613 under development by Seikagaku for the treatment of osteoarthritis in Japan.

Seikagaku initiates phase III study of SI-613

Seikagaku Corp <4548.T> :Says co announces the start of Phase III study of SI-613, a joint improving agent indicated for treatment of osteoarthritis, in Japan.

Seikagaku signs exclusive distribution agreement with Zimmer Biomet Holdings, Inc.

Seikagaku Corp <4548.T>:Say it signed an agreement with Zimmer Biomet Holdings, Inc. <ZBH.N> to grant Zimmer Biomet Holdings, Inc. the exclusive distribution rights in the U.S. on the joint function improver "VISCO-3TM".

Seikagaku signs exclusive worldwide license agreement for treatment for lumbar disc herniation

Seikagaku Corporation <4548.T>: Says the co entered into an exclusive worldwide license agreement(excluding Japan) with Ferring Pharmaceuticals for SI-6603(condoliase), a potential treatment for lumbar disc herniation .Says the co will receive an upfront payment of $5 million and milestone payments up to a maximum total amount of $90 million over multiple years upon future progress in development and commercialization.

Seikagaku signs agreement for license of lumbar disc herniation treatment agent with Ferring Pharmaceuticals

Seikagaku <4548.T>:Says it signed an agreement for overseas exclusive sale license of lumbar disc herniation treatment agent with Ferring Pharmaceuticals.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up